Research
Hormonal
New medications for T2DM, such as semaglutide, tirzepatide, and ertugliflozin, have been recently approved.
Healthcare providers should stay informed about newly approved medications for T2DM management.
StrongSupportsmedium confidence
We have also discussed some new promising candidates that have been approved recently by the US Food and Drug Administration for the treatment of T2DM, like semaglutide, tirzepatide, and ertugliflozin.
Why this rating
The claim is based on regulatory approval information.
Source
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Abhishek Kumar et al. · Current Diabetes Reviews · 2023
DOI 10.2174/0115733998261903230921102620
reviewCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →